The vaccine is here. Three questions about what happens next
Editor’s Commentary: With COVID-19 vaccines on the verge of rollout, policymakers and physicians should brace for a slew of queries
With COVID-19 vaccines on the verge of rollout, policymakers and physicians should brace for a slew of queries about the details.
The COVID-19 vaccine rollout is starting in the U.K., and is on the doorstep in the U.S. and Europe, building to a collective huge sigh of relief. The efficacy, at least for the first two, seems to be in the bag. But with the big issues addressed, questions about the details begin.
While the vaccines’ arrival is unquestionably an astonishing achievement in such a compressed time frame, obtaining regulatory authorization or approval is not the finish line. Getting them to enough people to achieve maximal effectiveness is the goal.
The vaccines’ success will depend not only on